Diabetes injection Byetta LAR faces Food and Drug Administration decision

Wed, 10 Mar 2010
Following clinical trials, considerable investment and a great deal of anticipation the long-action version of diabetes drug Byetta now faces an approval decision by the Food and Drug Administration. The drug is being sold by Amylin Pharmaceuticals alongside Eli Lilly and Co.

Byetta LAR is injected just once each week, and is thought to be a key drug in the future of Amylin. The drug is also thought to be crucial for Eli Lilly. The treatment will open up a different lifestyle for people with diabetes who use the drug .

Experts anticipate an approval for the drug, following an approval by the FDA of Victoza. Both drugs are similar to GLP-1, a human hormone that boosts the production of insulin to regulate blood glucose levels. However, some experts predict a delay in the approval process.
Leave a Comment
Login via Facebook, Yahoo! and Hotmail
or
Have your full say in the Diabetes Forum
Your comments may be moderated. Please report any spam, illegal, offensive or libellous posts.